Evidence map›Paper›PMID 31052182›Full record

ArticleInternational journal of molecular sciences2019

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.

Ananda Ayyappan Jaguva Vasudevan, Michèle J Hoffmann, Michael L C Beck, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A Schulz, Günter Niegisch

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Epigenetic Priming and Development of New Combination Therapy Approaches.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Epigenetics of Urological Cancers.International journal of molecular sciences · 2019
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ananda Ayyappan Jaguva VasudevanDepartment of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. ananda.ayyappan@med.uni-duesseldorf.de.ORCID 0000-0001-7049-9458
Michèle J HoffmannDepartment of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. michele.hoffmann@hhu.de.ORCID 0000-0002-6044-1671
Michael L C BeckDepartment of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. michael.beck@hhu.de.
Gereon PoschmannInstitute for Molecular Medicine, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. gereon.poschmann@hhu.de.
Patrick PetzschBiological and Medical Research Centre (BMFZ), Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. patrick.petzsch@hhu.de.ORCID 0000-0002-8355-5524
Constanze WiekDepartment of Otolaryngology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. constanze.wiek@hhu.de.
Kai StühlerInstitute for Molecular Medicine, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. kai.stuehler@hhu.de.
Karl KöhrerBiological and Medical Research Centre (BMFZ), Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. koehrer@hhu.de.
Wolfgang A SchulzDepartment of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. wolfgang.schulz@uni-duesseldorf.de.ORCID 0000-0002-2196-463X
Günter NiegischDepartment of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. guenter.niegisch@med.uni-duesseldorf.de.ORCID 0000-0001-6929-8691
Heinrich Heine University Düsseldorf · DEDüsseldorf University Hospital · DE

Funding

Brigitte und Dr. Konstanze-Wegener-Stiftung #11
6 · The paper itself

Abstract

Class I histone deacetylases (HDACs) generally promote cell proliferation and tumorigenesis, whereas class IIA HDACs like HDAC4 and HDAC5 may promote or impede cancer development in a tissue-dependent manner. In urothelial carcinoma (UC), HDAC5 is often downregulated. Accordingly, HDAC5 was weakly expressed in UC cell lines suggesting a possible tumor-suppressive function. We therefore characterized the effects of stable HDAC5 expression in four UC cell lines (RT112, VM-Cub-1, SW1710 and UM-UC-3) with different phenotypes reflecting the heterogeneity of UC, by assessing proliferation, clonogenicity and migration ability. Further, we detailed changes in the proteome and transcriptome by immunoblotting, mass spectrometry and RNA sequencing analysis. We observed that HDAC5 overexpression in general decreased cell proliferation, but in one cell line (VM-Cub-1) induced a dramatic change from an epitheloid to a mesenchymal phenotype, i.e., epithelial-mesenchymal transition (EMT). These phenotypical changes were confirmed by comprehensive proteomics and transcriptomics analyses. In contrast to HDAC5, overexpression of HDAC4 exerted only weak effects on cell proliferation and phenotypes. We conclude that overexpression of HDAC5 may generally decrease proliferation in UC, but, intriguingly, may induce EMT on its own in certain circumstances.

Indexed as

Cell ProliferationEpithelial-Mesenchymal TransitionCarcinomaCell Line, TumorHEK293 CellsHistone DeacetylasesHumansRNA, MessengerUrinary Bladder NeoplasmsUrotheliumHDAC5 protein, humanHistone DeacetylasesRNA, Messengerbladder cancerEMTepigeneticsHDAC4HDAC5histone deacetylaseproteomicsTGFβTNFαtranscriptomics

Identifiers

PMID31052182
PMCPMC6539474
OpenAlexW2942553874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.